Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review
Direct-acting antiviral drugs (DAAs) were recently approved for treating hepatitis C virus-related chronic hepatitis. As advanced chronic liver disease may predispose patients to thrombotic events, it is still uncertain whether DAAs may influence the actual risk of major arterial and venous thrombotic events. We performed a systematic review to assess the incidence of major vascular events in patients receiving DAAs for HCV chronic hepatitis during phase-III randomized controlled trials (RCTs). Two reviewers identified studies through Pubmed database until October 2015. Reporting and incidence of any vascular events were compared with reporting and incidence of major bleeding, anemia (a prespecified safety outcome) and headache (a common non-prespecified safety outcome). 33 RCTs, encompassing 14,764 patients, were included. Only 13 (39%) and 4 (12%) RCTs provide data on any arterial or venous events, respectively. Occurrence of anemia and headache is reported in all studies. Crude unweighted rate of major arterial events is 0.16% (95% CI 0.10–0.24) of the total included population and 0.47% in those 13 RCTs reporting data. Crude unweighted rate of major venous events is 0.03% of the total included population (95% CI 0.01–0.08) and 0.22% in those four RCTs reporting data. Crude unweighted rate of major bleeding is 0.07% (95% CI 0.03–0.1). Incidence of thrombotic events in HCV patients receiving DAAs may be low, but an incorrect estimation cannot be excluded.
KeywordsChronic hepatitis Direct-acting antiviral drugs Myocardial infarction Underreporting Venous thromboembolism
ETP performed data collection and analysis, manuscript writing and final approval. AS was involved in study design, data interpretation, manuscript writing and final approval. LG performed data collection. VEAG, LM and LG performed data interpretation, manuscript editing and final approval.
Compliance with ethical standards
Conflict of interest
Statement of human and animal rights
This article does not contain any studies with human participants or animals performed by any of the authors.
- 7.Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694CrossRefPubMedGoogle Scholar
- 9.Loke YK, Price D, Herxheimer A (2011) Chapter 14: Adverse effects. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. http://www.handbook.cochrane.org
- 15.Reddy KR, Zeuzem S, Zoulim F, Weiland O, Horban A, Stanciu C et al (2015) Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect Dis 15(1):27–35CrossRefPubMedGoogle Scholar
- 16.Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y et al (2015) Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 163(1):1–13CrossRefPubMedGoogle Scholar
- 18.Izumi N, Hayashi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H et al (2014) Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol 49(5):941–953CrossRefPubMedGoogle Scholar
- 28.Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H et al (2015) Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 15(6):645–653CrossRefPubMedGoogle Scholar
- 30.Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A et al (2014) ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 147(2):359.e1–365.e1CrossRefGoogle Scholar
- 33.Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV et al (2014) Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 384(9941):403–413CrossRefPubMedGoogle Scholar
- 34.Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y et al (2014) Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 384(9941):414–426CrossRefPubMedGoogle Scholar
- 49.European Centre for Disease Prevention and Control (2016) Systematic review on hepatitis B and C prevalence in the EU/EEA. ECDC, StockholmGoogle Scholar